

Resolution

of the Federal Joint Committee on a Finding in the Procedure of Routine Practice Data Collection and Evaluations according to Section 35a, paragraph 3b SGB V:

Odronextamab (relapsed or refractory diffuse large B-cell lymphoma) – Submission of study protocol and statistical analysis plan

of 22 January 2026

At their session on 22 January 2026, the Federal Joint Committee (G-BA) decided the following in the procedure of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient odronextamab (relapsed or refractory diffuse large B-cell lymphoma):

- I. The routine practice data collection will not be carried out as it was found that the pharmaceutical company has not fulfilled their obligation - required by resolution of 17 July 2025 - to prepare a statistical analysis plan and study protocol prior to the implementation of the routine practice data collection.
- II. The resolution will enter into force on the day of its publication on the website of the G-BA on 22 January 2026.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 22 January 2026

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken